Christine R. Coyne
About Christine R. Coyne
Christine R. Coyne (age 57) joined Iterum Therapeutics as Chief Commercial Officer in July 2025. She previously held CCO roles at Innoviva Specialty Therapeutics (Jan 2023–Oct 2024) and SCYNEXIS (May 2021–Nov 2022), and senior commercial leadership positions at Paratek Pharmaceuticals, BTG, Auxilium Pharmaceuticals, and Endo International. Coyne holds an MBA from Eastern University and a B.A. in Foreign Languages from West Chester University . As a baseline prior to her appointment, company TSR and profitability trends are shown below.
Company performance baseline (prior to Coyne’s appointment):
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Total Shareholder Return (Value of initial $100) | 33.50 | 234.92 | 210.71 |
| Net Income ($USD Thousands) | (44,434) | (38,371) | (24,774) |
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| EBITDA ($USD) | -28,583,000* | -45,718,000* | -18,412,000* |
| Values retrieved from S&P Global. |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Innoviva Specialty Therapeutics | Chief Commercial Officer | Jan 2023–Oct 2024 | Led commercial operations for specialty therapeutics portfolio . |
| SCYNEXIS | Chief Commercial Officer | May 2021–Nov 2022 | Led commercialization strategy in anti-infectives . |
| Paratek Pharmaceuticals | Senior Vice President, Commercial | 2017–May 2021 | Scaled commercial organization and go-to-market . |
| BTG (Boston Scientific group) | Vice President, Strategy Business Development | 2014–2017 | Drove portfolio strategy and BD initiatives . |
| Auxilium Pharmaceuticals | Senior Director, Portfolio Strategy and Brand Managed Markets | Prior to 2014 | Managed portfolio and payer strategies . |
| Endo International plc | Senior Director, Marketing | Prior to Auxilium | Led brand marketing in specialty pharma . |
External Roles
No public company board roles or committee positions disclosed for Coyne .
Fixed Compensation
Not disclosed for Coyne in the 2025 DEF 14A (no base salary, target bonus, or cash compensation figures provided). Executive compensation processes and target bonus frameworks are described for other NEOs, but Coyne was appointed in July 2025 and not covered in the 2024/2023 NEO tables .
Performance Compensation
No performance award grants (RSUs/PSUs/options) and no 2025 incentive metrics or payouts disclosed for Coyne as of the 2025 proxy. The equity plan outlines eligibility and treatment in corporate transactions, but individual CCO awards/metrics were not reported .
Equity Ownership & Alignment
| Holder | Shares Beneficially Owned | % of Shares Outstanding | Notes |
|---|---|---|---|
| Christine R. Coyne | — | *less than 1% | No reportable shares/options/warrants exercisable within 60 days; group totals exclude her . |
Policy signals:
- Anti-hedging and anti-pledging: Directors, officers, and employees are prohibited from hedging, pledging, short sales, and options trading in company securities .
- Clawback: Compensation Recovery Policy adopted in Oct 2023 to comply with Nasdaq Rule 5608 (Rule 10D-1), mandating recovery of erroneously awarded incentive-based compensation after accounting restatements .
- Equity plan authority: Board may reprice options or SARs without prior shareholder approval under the 2018 Plan, a governance sensitivity for shareholders .
Eligibility and plan mechanics:
- Eligibility: Executives are eligible under the 2018 Equity Incentive Plan and sub-plan; awards are discretionary .
- Corporate transaction/change-in-control: Unvested awards may be accelerated upon qualifying termination around change-in-control per 2018 Plan; detailed definitions of “change in control,” “cause,” and “good reason” apply .
Employment Terms
Coyne’s offer letter, severance, and change-of-control protections were not disclosed in the 2025 DEF 14A or recent 8-K filings. The company provides severance and change-of-control economics for other NEOs (CEO/CFO), but Coyne-specific terms are absent .
General plan-level treatment for equity acceleration in qualifying change-of-control scenarios is described under the 2018 Plan .
Compensation committee oversight and use of independent consultants (Coda Advisors) are described; clawback policy and insider trading restrictions apply to executive officers .
Investment Implications
- Near-term disclosure gap: Coyne’s cash compensation, target bonus metrics, and equity grants are not yet disclosed; investors should watch for an 8-K or next proxy detailing her package, vesting schedules, and performance metrics to assess pay-for-performance alignment and retention incentives .
- Alignment risk vs. policy mitigants: No reportable beneficial ownership at appointment reduces immediate “skin in the game,” partially offset by strict anti-hedging/pledging and clawback policies .
- Equity plan governance sensitivity: Ability to reprice options without shareholder approval under the 2018 Plan is a red flag for some governance frameworks; monitoring actual usage is prudent .
- Baseline performance context: Company’s TSR rebounded strongly in 2023 but moderated in 2024; net losses narrowed. Establishing Coyne’s commercial KPIs tied to oral sulopenem’s trajectory will be key to evaluating future incentive payouts and insider selling pressure as any new grants begin to vest .
Data limitations: No Coyne-specific compensation or insider ownership filings were located in the latest proxy and 8-Ks; we will update upon new disclosures.
References: